Neuromyelitis optica spectrum disorder

Beekman, Janine B.; Keisler, Aysha; Pedraza, Omar; Haramura, Masayuki; Gianella‐Borradori, Athos; Katz, Eliezer; Ratchford, John N.; Barron, Gerard; Cook, Lawrence J.; Behne, Jacinta M.; Blaschke, Terrence F.; Smith, Terry J.; Yeaman, Michael R.

doi:10.1212/nxi.0000000000000580

Cited by 96 publications

(61 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the majority of cases, NMOSDs are associated with serum immunoglobulin G (IgG) autoantibodies (Abs) targeting the astrocyte aquaporin-4 (AQP4) water channel (11,12). Patients typically suffer from recurrent attacks of severe optic neuritis and/or myelitis (13,14) and, less frequently, brainstem or brain involvement (15,16), leading to a diverse range of symptoms, of which severe pain is one of the most frequent and disabling (2,(17)(18)(19)(20)(21)(22)(23)(24)(25)(26). Chronic pain occurs in NMOSD with an estimated prevalence between 72 and 86% (2,18,27,28).…”

Section: Introductionmentioning

confidence: 99%

Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies

2020

View full text Add to dashboard Cite

Neuromyelitis optica spectrum disorders (NMOSDs) and myelin oligodendrocyte glycoprotein-antibody-associated disease (MOGAD) are autoimmune inflammatory disorders of the central nervous system (CNS). Pain is highly prevalent and debilitating in NMOSD and MOGAD with a severe impact on quality of life, and there is a critical need for further studies to successfully treat and manage pain in these rare disorders. In NMOSD, pain has a prevalence of over 80%, and pain syndromes include neuropathic, nociceptive, and mixed pain, which can emerge in acute relapse or become chronic during the disease course. The impact of pain in MOGAD has only recently received increased attention, with an estimated prevalence of over 70%. These patients typically experience not only severe headache, retrobulbar pain, and/or pain on eye movement in optic neuritis but also neuropathic and nociceptive pain. Given the high relevance of pain in MOGAD and NMOSD, this article provides a systematic review of the current literature pertaining to pain in both disorders, focusing on the etiology of their respective pain syndromes and their pathophysiological background. Acknowledging the challenge and complexity of diagnosing pain, we also provide a mechanism-based classification of NMOSD- and MOGAD-related pain syndromes and summarize current treatment strategies.

show abstract

Section: Introductionmentioning

confidence: 99%

Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies

2020

View full text Add to dashboard Cite

show abstract

“…It was reported that the primary fatigue in patients with MS may stem from centrally mediated processes caused by the conduction issues such as demyelination or axonal loss in CNS [7]. In NMOSD and MS, fatigue has been reported to impair activities of the daily living [6,[8][9][10]. In MS patients, the prevalence of fatigue was reported to be 50% to 90%, and more than 20 trials were performed to determine the appropriate treatment for fatigue [6,11].…”

Section: Introductionmentioning

confidence: 99%

Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis

et al. 2020

View full text Add to dashboard Cite

ObjectiveTo investigate the difference of fatigue and pain in patients with neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS). MethodsData from the Modified Fatigue Impact Scale (MFIS) and Pain Effects Scale (PES) were compared between 51 NMOSD and 85 MS patients. Each score was compared in each disease group with or without clinical abnormalities. Since almost no MS patients are without brain magnetic resonance imaging abnormalities, volumetry analysis by the Lesion Segmentation Tool and statistical parametric mapping 12 were added to obtain total lesion volume and intracranial volume in MS patients, and the correlations between total lesion volume/intracranial volume and each score were investigated. ResultsCompared to the MS group, the NMOSD group showed a higher PES score (median, 15.0 vs. 7.0, P = 0.045), no difference in MFIS, and an increased percentage of patients with extended spinal cord lesions (58.8% vs. 8.2%, P < 0.001). Moreover, NMOSD and MS patients with extended spinal cord lesions tended to demonstrate higher PES scores than those without. A positive correlation between MFIS and PES were found in patients with NMOSD and MS. On the other hand, MS patients showed a higher percentage of brain abnormalities (80.4% vs. 97.6%, P = 0.001) and a positive correlation between total lesion volume/intracranial volume and MFIS (Spearman's ρ = 0.50, P = 0.033). ConclusionsThe origin of fatigue may be associated with spinal cord lesions causing pain in NMOSD patients, but with brain lesions in MS patients.

show abstract

“…15,17,18 Depression and psychological distress affect subjective well-being in patients with NMOSD. [19][20][21][22] However, no studies have focused on stigma and NMOSD. The purpose of this study was to assess stigmatization and its impact on patients living with NMOSD.…”

Section: Introductionmentioning

confidence: 99%

Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder

Meca-Lallana¹,

Prefasi²,

Pérez‐Miralles³

et al. 2021

PPA

View full text Add to dashboard Cite

Background Perception of stigma was associated with low self-esteem, psychological problems, and decreased health-seeking behavior among patients with different neurological disorders. The purpose of this study was to assess stigmatization and its impact in patients with neuromyelitis optica spectrum disorder (NMOSD). Methods A non-interventional study was conducted at thirteen neuroimmunology clinics in Spain. Patients with a diagnosis of NMOSD (2015 Wingerchuk criteria) were included. The 8-item Stigma Scale for Chronic Illness (SSCI-8), the Expanded Disability Status Scale (EDSS), the 29-item Multiple Sclerosis Impact Scale (MSIS-29), the Beck Depression Inventory-Fast Screen (BDI-FS), the MOS Pain Effects Scale (MOS-PES) and the Fatigue Impact Scale for Daily Use (D-FIS) were used to assess the perception of stigma, disability, quality of life, mood, pain, and fatigue, respectively. Associations between outcome measures were analyzed using Spearman’s rank correlation. Results Seventy-one patients were studied (mean age: 47.4 years ± 14.9, 81.7% female, mean time since disease onset: 9.9 years ± 8.1). The median EDSS score was 3.0 (interquartile range 1.5, 4.5). Stigma prevalence was 61.4% (n=43). Thirty-one patients (43.6%) had depression. The SSCI-8 score showed a significant correlation with both physical (rho=0.576, p<0.0001) and psychological (rho=0.608, p<0.0001) MSIS-29 scales scores, EDSS score (rho=0.349, p=0.0033), BDI-FS score (rho= 0.613, p<0.0001), MOS-PES score (rho= 0.457, p<0.0001), and D-FIS score (rho=0.556, p<0.0001). Conclusion Stigma is a common phenomenon affecting over 6 out of 10 patients with NMOSD. Understanding stigma may be useful to develop educational strategies improving NMOSD knowledge.

show abstract

Neuromyelitis optica spectrum disorder

Cited by 96 publications

References 44 publications

Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies

Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies

Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis

Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder

Contact Info

Product

Resources

About